3D conformal HDR-brachy- and external beam therapy plus simultaneous Cisplatin for high-risk cervical cancer: Clinical experience with 3 year follow-up

摘要: Abstract Background and purpose To assess feasibility, safety effectiveness of CT–based 3D conformal external beam radiotherapy (EBRT) plus concurrent cisplatin MRI–based HDR-brachytherapy (HDR-BT) in the treatment advanced cervical cancer. Patients methods A total 48 patients with cancer, treated EBRT simultaneous chemotherapy (40mg/m 2 body surface per week for 5 weeks) HDR-BT, were included analysis. Results All completed as planned 90% received at least four cycles chemotherapy. Frequencies CTC grade 3 anaemia, 3–4 leucopenia thrombocytopenia 4, 23 10%, respectively. Two developed deep vein thrombosis one non-fatal pulmonary embolism. Grade 4 genitourinary late side effects (bladder) occurred patients. No gastrointestinal observed. Complete response (CR) was obtained 45 (94%). After a median follow-up 33 months, 27 disease free. Actuarial overall survival years 61%, progression free 51% continuous complete remission true pelvis 85%. Conclusions HDR-BT appears to be safe effective, although acute haematological toxicity is increased. Gastrointestinal morbidity minimal when prospectively applying dose volume constraints adaptation.